Lebwohl David 4/A
4/A · Intellia Therapeutics, Inc. · Filed Mar 4, 2022
Insider Transaction Report
Form 4/AAmended
Lebwohl David
EVP, Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-01+20,203→ 20,203 totalExercise: $79.85Exp: 2032-02-28→ Common Stock (20,203 underlying)
Footnotes (2)
- [F1]The original Form 4 incorrectly reported the number of options granted as 13,816.
- [F2]This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.